实用癌症杂志
實用癌癥雜誌
실용암증잡지
THE PRACTICAL JOURNAL OF CANCER
2014年
12期
1625-1627
,共3页
周雪峰%潘骥群%周剑波%陈卫宏%季祥%张霞
週雪峰%潘驥群%週劍波%陳衛宏%季祥%張霞
주설봉%반기군%주검파%진위굉%계상%장하
胰腺癌%放射治疗%化学治疗
胰腺癌%放射治療%化學治療
이선암%방사치료%화학치료
Pancreatic cancer%Radiotherapy%Chemotherapy
目的:观察三维适形放疗同步GemOx方案化疗治疗局部晚期胰腺癌的疗效和不良反应。方法2007年8月-2011年8月,24例患者均经病理学或临床诊断为局部晚期胰腺癌,接受三维适形放疗,计划照射剂量6MV-X线DT 60~70 Gy,2~2.5 Gy/次;同时化疗2周期,方案为GemOx(吉西他滨1000 mg/m2,d1、d8;奥沙利铂130 mg/m2,d1)。在放疗后维持GemOx方案化疗2周期,每21 d重复一次,观察疗效、临床收益反应和不良反应。结果24例患者完全缓解1例(4.2%),部分缓解10例(41.6%),稳定12例(50.0%),进展1例(4.2%),有效率为45.8%(11/24);6个月生存率为87.5%(21/24),12个月为58.3%(14/24),24个月为12.5%(3/24),中位生存11.8个月。 CBR评估:未行黄疽引流者3例,治疗后黄疸消退2例(66.7%);治疗前伴腹背部疼痛21例(87.5%),治疗后止痛有效率为90.5%(19/21)。患者一般状况Karnofsky评分提高20分以上者18例,占75.0%;发生恶心、呕吐54.2%(13/24)、白细胞下降66.7%(16/24)、血小板下降37.5%(9/24),其中Ⅰ、Ⅱ度分别为10例(41.7%)、12例(50.0%)、5例(20.8%),Ⅲ度分别为3例(12.5%)、4例(16.7%)、3例(12.5%),此外血小板下降者中Ⅳ度1例(4.2%)。结论三维适形放疗联合GemOx方案化疗治疗局部晚期胰腺癌有较好的缓解症状和局部控制作用,可以提高患者的生存时间和生活质量,且不良反应可以控制,值得推广应用。
目的:觀察三維適形放療同步GemOx方案化療治療跼部晚期胰腺癌的療效和不良反應。方法2007年8月-2011年8月,24例患者均經病理學或臨床診斷為跼部晚期胰腺癌,接受三維適形放療,計劃照射劑量6MV-X線DT 60~70 Gy,2~2.5 Gy/次;同時化療2週期,方案為GemOx(吉西他濱1000 mg/m2,d1、d8;奧沙利鉑130 mg/m2,d1)。在放療後維持GemOx方案化療2週期,每21 d重複一次,觀察療效、臨床收益反應和不良反應。結果24例患者完全緩解1例(4.2%),部分緩解10例(41.6%),穩定12例(50.0%),進展1例(4.2%),有效率為45.8%(11/24);6箇月生存率為87.5%(21/24),12箇月為58.3%(14/24),24箇月為12.5%(3/24),中位生存11.8箇月。 CBR評估:未行黃疽引流者3例,治療後黃疸消退2例(66.7%);治療前伴腹揹部疼痛21例(87.5%),治療後止痛有效率為90.5%(19/21)。患者一般狀況Karnofsky評分提高20分以上者18例,佔75.0%;髮生噁心、嘔吐54.2%(13/24)、白細胞下降66.7%(16/24)、血小闆下降37.5%(9/24),其中Ⅰ、Ⅱ度分彆為10例(41.7%)、12例(50.0%)、5例(20.8%),Ⅲ度分彆為3例(12.5%)、4例(16.7%)、3例(12.5%),此外血小闆下降者中Ⅳ度1例(4.2%)。結論三維適形放療聯閤GemOx方案化療治療跼部晚期胰腺癌有較好的緩解癥狀和跼部控製作用,可以提高患者的生存時間和生活質量,且不良反應可以控製,值得推廣應用。
목적:관찰삼유괄형방료동보GemOx방안화료치료국부만기이선암적료효화불량반응。방법2007년8월-2011년8월,24례환자균경병이학혹림상진단위국부만기이선암,접수삼유괄형방료,계화조사제량6MV-X선DT 60~70 Gy,2~2.5 Gy/차;동시화료2주기,방안위GemOx(길서타빈1000 mg/m2,d1、d8;오사리박130 mg/m2,d1)。재방료후유지GemOx방안화료2주기,매21 d중복일차,관찰료효、림상수익반응화불량반응。결과24례환자완전완해1례(4.2%),부분완해10례(41.6%),은정12례(50.0%),진전1례(4.2%),유효솔위45.8%(11/24);6개월생존솔위87.5%(21/24),12개월위58.3%(14/24),24개월위12.5%(3/24),중위생존11.8개월。 CBR평고:미행황저인류자3례,치료후황달소퇴2례(66.7%);치료전반복배부동통21례(87.5%),치료후지통유효솔위90.5%(19/21)。환자일반상황Karnofsky평분제고20분이상자18례,점75.0%;발생악심、구토54.2%(13/24)、백세포하강66.7%(16/24)、혈소판하강37.5%(9/24),기중Ⅰ、Ⅱ도분별위10례(41.7%)、12례(50.0%)、5례(20.8%),Ⅲ도분별위3례(12.5%)、4례(16.7%)、3례(12.5%),차외혈소판하강자중Ⅳ도1례(4.2%)。결론삼유괄형방료연합GemOx방안화료치료국부만기이선암유교호적완해증상화국부공제작용,가이제고환자적생존시간화생활질량,차불량반응가이공제,치득추엄응용。
Objective To observe the curative effect and adverse reactions of three-dimensional conformal radiotherapy and GemOx chemotherapy for locally adanced pancreatic cancer .Methods 24 patients both confirmed by pathology or clinical diagnosis as locally adanced pancreatic cancer received three-dimensional conformal radiotherapy ,plan the 6 MV-X line doses of DT 60~70 Gy,2~2.5 Gy/time,and 2 cycles of GemOx chemotherapy ( gemcitabine 1000 mg/m2 ,d1,d8;oxaliplatin 130 mg/m2,d1),maintain 2 cycles of GemOx chemotherapy after radiotherapy ,each cycle was 21 days,clinical curative effect,benefit re-action and adverse reactions were observed .Results Among 24 patients,there were complete remission 1 case (4.2%),partial remission 10 cases(41.6%),stable 12 cases (50.0%),progression 1 case (4.2%),effective rate was 45.8%;6-month surviv-al rate was 87.5%(21/24),12-month survival rate was 58.3%(14/24),24-month survival rate was 12.5%(3/24),the medi-an survival time was 11.8 months;CBR assessment:without jaundice drainage in 3 cases,jaundice subsidised after treatment in 2 cases (66.7%),21 cases of abdominal pain in the back before treatment (87.5%),after treatment the effective rate was 90.5%(19/21);Patients'general Karnofsky score increased by 20 points in 18 cases,which was above 75.0%;Adverse reaction were nausea、vomiting in 13 cases (54.2%),leukocytopenia 16 cases (66.7%),thrombocytopenia 9 cases degree (37.5%),of which Ⅰdegree and Ⅱdegree were respectively 10 cases(41.7%),12 cases(50.0%),5 cases(20.8%);Ⅲ degree were re-spectively 3 cases (12.5%),4 (16.7%),3 cases (12.5%);Ⅳdegree thrombocytopenia 1 case(4.2%).Conclusion Three-dimensional conformal radiotherapy combined GemOx for locally adanced pancreatic cancer has good relieve symptoms and local control effect ,it can improve survival time and the quality of life of patients with tolerable adverse reactions ,it is worthy of clinical popularization .